MERS-CoV vaccine candidates in development: The current landscape (Q38809401)

6 September 2017

1 reference

22 October 2022

MERS-CoV vaccine candidates in development: The current landscape (English)

1 reference

Middle East respiratory syndrome coronavirus

6 September 2017

0 references

1

Kayvon Modjarrad

1 reference

PubMed ID

27083424

6 September 2017

language of work or name

English

0 references

publication date

12 April 2016

1 reference

PubMed ID

27083424

6 September 2017

3 June 2016

1 reference

22 October 2022

6

1 reference

inferred from page(s)

published in

Vaccine

2 references

6 September 2017

22 October 2022

34

1 reference

6 September 2017

26

1 reference

6 September 2017

2982-2987

1 reference

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

6 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Probable transmission chains of Middle East respiratory syndrome coronavirus and the multiple generations of secondary infection in South Korea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

A decade after SARS: strategies for controlling emerging coronaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Detection of coronaviruses in bats of various species in Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Diversity of coronavirus in bats from Eastern Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Middle East respiratory syndrome coronavirus antibody reactors among camels in Dubai, United Arab Emirates, in 2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Antibodies against MERS coronavirus in dromedary camels, Kenya, 1992-2013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

MERS coronavirus in dromedary camel herd, Saudi Arabia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Evidence for camel-to-human transmission of MERS coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

MERS: emergence of a novel human coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Anti-SARS coronavirus agents: a patent review (2008 - present).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Evaluation of candidate vaccine approaches for MERS-CoV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Receptor-binding domain-based subunit vaccines against MERS-CoV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Crystal Structure of the Receptor-Binding Domain from Newly Emerged Middle East Respiratory Syndrome Coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Family cluster of Middle East respiratory syndrome coronavirus infections, Tunisia, 2013.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Hospital outbreak of Middle East respiratory syndrome coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Hospital-associated Middle East respiratory syndrome coronavirus infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Middle East respiratory syndrome coronavirus infections in health care workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Rapid generation of a mouse model for Middle East respiratory syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Animal models of Middle East respiratory syndrome coronavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.03.104

Estimation of MERS-Coronavirus Reproductive Number and Case Fatality Rate for the Spring 2014 Saudi Arabia Outbreak: Insights from Publicly Available Data

7 January 2021

1 reference

12 December 2020

1 reference

12 December 2020

Hospital-associated Middle East respiratory syndrome coronavirus infections.

1 reference

12 December 2020

Middle East respiratory syndrome novel corona MERS-CoV infection. Epidemiology and outcome update

1 reference

12 December 2020

Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation

1 reference

12 December 2020

Update: Severe respiratory illness associated with Middle East Respiratory Syndrome Coronavirus (MERS-CoV)--worldwide, 2012-2013.

1 reference

12 December 2020

10.1016/J.VACCINE.2016.03.104

Identifiers

DOI

1 reference

6 September 2017

0 references

1 reference

PubMed ID

27083424